406233-34-9

Usage

Chemical Properties

Yellow Solid

Uses

Intermediate in the production of ABT 737

Upstream product

• 406233-31-6 4-fluoro-3-nitrobenzenesulfonamide 
• 406233-32-7 (R)-3-(2-nitro-4-sulfamoylphenylamino)-4-phenylsulfanylbutyric acid tert-butyl ester 
• 6668-56-0 4-fluoro-3-nitrobenzene-1-sulfonyl chloride 
• 108-98-5 thiophenol 
• 1493-27-2 ortho-nitrofluorobenzene 
• 882-33-7 diphenyldisulfane 
• 14204-24-1 N-(phenylthio)succinimide 
• 870812-31-0 (3R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide 
• 406233-33-8 (R)-3-(2-nitro-4-sulfamoylphenylamino)-4-phenylsulfanylbutyric acid 
• 124-40-3 dimethyl amine 

Downstream Products

• 406228-55-5 (R)-4-(3-dimethylamino-1-phenylsulfanylmethylpropylamino)-N-[4-(4,4-dimethylpiperidin-1-yl)benzoyl]-3-nitrobenzenesulfonamide 

Relevant academic research and scientific papers

iSPAAC: Isomer-Free Generation of a Bcl-xL-Inhibitor in Living Cells

Strain-promoted azide–alkyne cycloadditions (SPAAC) have proven extremely useful for labeling of biomolecules, but typically produce isomeric mixtures. This is not appropriate for the formation of bioactive molecules in living cells. Here, the first use o

APOPTOSIS-INDUCING AGENTS

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti apoptotic Bcl-xL protein.

BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

BCL-2 INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to Bcl-2 inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors

BCL-2 INHIBITORS

The present invention relates to Bcl-2 inhibitors and their use in the treatment of cell proliferative diseases such as cancer.

ARYLSULFONAMIDE COMPOUNDS

The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mim

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo

Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-XL function, is described. Lead compounds generated by NMR screening and directed parallel synthesis displayed sub-μM binding but were strongly deactivated in the presence of serum. The dominant component of serum deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of inhibitors bound to both Bcl-X L and HSA domain III indicated two potential optimization sites for separation of affinities. Modifications at both sites resulted in compounds with improved Bcl-XL binding and greatly increased activity in the presence of human serum, culminating in 73R, which bound to Bcl-XL with a Ki of 0.8 μM. In a cellular assay 73R reversed the protection afforded by Bcl-XL overexpression against cytokine deprivation in FL5.12 cells with an EC50 of 0.47 μM. 73R showed little effect on the viability of the human non small cell lung cancer cell line A549. However, consistent with the proposed mechanism, 73R potentiated the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of paclitaxel in a mouse xenograft model.

N-acylsulfonamide apoptosis promoters

N-Benzoyl arylsulfonamides having the formula are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.